Several randomized controlled trials and meta-analyses demonstrate that rectally administered nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce the risk of post-endoscopic retrograde cholangiopancreatography (PEP) by around 50% and also decrease the severity of PEP in both high-risk and average-risk patients. The European Society of Gastrointestinal Endoscopy recommends rectal NSAIDs as a grade A recommendation for nearly all ERCP patients to help prevent PEP. While rectal NSAID use has increased in clinical practice, some healthcare providers and patients are uncomfortable with the rectal administration method.